Glaxosmi. Pharma

Which are the latest news on Glaxosmi. Pharma?

Why is Glaxosmithkline Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Glaxosmithkline Pharmaceuticals Ltd's stock price is rising to 2,958.60, following a trend reversal after four days of decline and outperforming its sector. Despite a decline in investor participation, the stock's strong historical performance and financial health support its upward movement.

As of 05-Sep, Glaxosmithkline Pharmaceuticals Ltd's stock price is rising, currently at 2,958.60, with a change of 23.25 (0.79%) upwards. This rise can be attributed to several factors. Notably, the stock has experienced a trend reversal, gaining after four consecutive days of decline. Additionally, it has outperformed its sector by 1.4% today, indicating a positive performance relative to its peers.<BR><BR>In terms of longer-term performance, the stock has shown significant resilience, with a year-to-date increase of 19.74%, compared to a decline of 10.21% in the benchmark Sensex. Over the past three years, Glaxosmithkline has delivered an impressive 107.64% return, far exceeding the Sensex's 16.59% increase during the same period. This consistent performance, along with a high return on equity (ROE) of 45.70% and being net-debt free, reflects strong management efficiency and financial health, which can instill investor confidence.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 62.87% against the five-day average. Despite this, the stock remains liquid enough for trading, which may help sustain its upward movement. Overall, the combination of a recent trend reversal, strong historical performance, and solid financial metrics contributes to the current rise in Glaxosmithkline Pharmaceuticals Ltd's stock price.

Who are in the management team of Glaxosmi. Pharma?

The management team of Glaxosmi. Pharma includes Renu S Karnad (Chairperson), Bhushan Akshikar (Managing Director), J. Chandy (Whole Time Director & CFO), and several independent directors, bringing diverse expertise to the company.

The management team of Glaxosmi. Pharma includes the following key individuals:<BR><BR>1. **Renu S Karnad** - Chairperson<BR>2. **Bhushan Akshikar** - Managing Director<BR>3. **J. Chandy** - Whole Time Director & CFO<BR>4. **D Sundaram** - Independent Director<BR>5. **P V Bhide** - Independent Director<BR>6. **A N Roy** - Independent Director<BR>7. **Sunita Maheshwari** - Independent Director<BR>8. **Manu Anand** - Independent Director<BR>9. **A A Nadkarni** - Company Secretary & Compliance Officer<BR>10. **Subesh Williams** - Director<BR><BR>This team brings a diverse range of expertise and leadership to the company. If you have any more questions about Glaxosmi. Pharma or its operations, feel free to ask!

What does Glaxosmi. Pharma do?

GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GSK Plc., operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 938 Cr and a net profit of 237 Cr for June 2026, with a market cap of INR 52,069 Cr. Key metrics include a P/E ratio of 49.00, a dividend yield of 1.84%, and a return on equity of 45.02%.

Overview:<BR>GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History:<BR>The company is incorporated as a subsidiary of GSK Plc. and is headquartered in Mumbai. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 938 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 237 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 52,069 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 49.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.84%<BR>- Debt Equity: -1.21<BR>- Return on Equity: 45.02%<BR>- Price to Book: 23.20<BR><BR>Contact Details:<BR>- Address: GSK House, Dr Annie Besant Road Worli Mumbai Maharashtra : 400030<BR>- Tel: 91-022-24959595<BR>- Email: askus@gsk.com<BR>- Website: http://www.gsk-india.com

Who are the peers of the Glaxosmi. Pharma?

Peers of Glaxosmi. Pharma include Glenmark Pharma, Biocon, Alkem Lab, Abbott India, Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Emcure Pharma, and Wockhardt. Glaxosmi. Pharma has a 1-year return of 9.69%, with management risk rated as Average and capital structure rated as Excellent.

Peers: The peers of Glaxosmi. Pharma are Glenmark Pharma, Biocon, Alkem Lab, Abbott India, Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Glaxosmi. Pharma, and Ajanta Pharma, while Good management risk is found at Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Emcure Pharma, and Average management risk is noted at Biocon and Wockhardt. Growth is Excellent at Anthem Bioscienc and Emcure Pharma, Average at Glenmark Pharma, Biocon, and Abbott India, and Below Average at Alkem Lab, Glaxosmi. Pharma, Ipca Labs, Gland Pharma, and Ajanta Pharma. Capital Structure is Excellent at Alkem Lab, Abbott India, Glaxosmi. Pharma, Ajanta Pharma, and Gland Pharma, Good at Glenmark Pharma and Emcure Pharma, and Below Average at Biocon.<BR><BR>Return Snapshot: Ipca Labs has the highest 1-year return at 43.03%, while Abbott India has the lowest at -17.91%. Glaxosmi. Pharma's 1-year return of 9.69% is higher than Abbott India's but lower than Ipca Labs'. Additionally, Biocon and Alkem Lab have negative six-month returns.

How big is Glaxosmi. Pharma?

As of 31st August, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 52,069.00 Cr, with recent net sales of 3,954.94 Cr and net profit of 1,068.15 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 52,069.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,954.94 Cr, while the sum of Net Profit for the same period is 1,068.15 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 2,267.42 Cr and Total Assets totaling 4,190.02 Cr.

Should I buy, sell or hold Glaxosmithkline Pharmaceuticals Ltd?

Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?

GlaxoSmithKline Pharmaceuticals Ltd's latest results show a year-on-year net profit increase of 15.69% and revenue growth of 16.55%, but sequential declines in profit and revenue, along with reduced operating margins, indicate operational challenges. Overall, the financial trend is considered 'FLAT,' suggesting a cautious outlook for investors.

GlaxoSmithKline Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a year-on-year net profit increase of 15.69%, reaching ₹237.18 crores, and a revenue growth of 16.55% year-on-year, which indicates some strength in its topline performance. However, there are significant concerns regarding profitability and operational challenges.<BR><BR>Sequentially, the net profit declined by 14.64% and revenue fell by 5.71% compared to the previous quarter. This decline raises questions about the sustainability of demand and suggests potential operational headwinds. Additionally, the operating margin contracted to 31.49%, down from 35.26% in the previous quarter, reflecting increased cost pressures.<BR><BR>Overall, while there are positive indicators in terms of year-on-year growth, the sequential declines and margin compression suggest that the company's recent performance is not entirely favorable. Analysts have classified the financial trend as 'FLAT,' indicating a cautious outlook moving forward. Investors may need to monitor how the company addresses these challenges in upcoming quarters.

Has Glaxosmithkline Pharmaceuticals Ltd declared dividend?

Yes, Glaxosmithkline Pharmaceuticals Ltd has declared a dividend of 570%, amounting to ₹12 per share, with an ex-date of November 7, 2024. While recent total returns have shown volatility, the company has demonstrated positive growth over the longer term, particularly in the 2 to 5-year periods.

Glaxosmithkline Pharmaceuticals Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 570%<BR>- Amount per share: 12 per share<BR>- Ex-date: Nov-07-2024<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%.<BR><BR>In the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%.<BR><BR>Over the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%.<BR><BR>In the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%.<BR><BR>For the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%.<BR><BR>In the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culminating in a total return of 76.36%.<BR><BR>Over the 5 Years period, the price return was 62.24%, the dividend return was 15.06%, resulting in a total return of 77.3%.<BR><BR>Overall, Glaxosmithkline Pharmaceuticals Ltd has declared a significant dividend, and while the recent total returns show some volatility, the longer-term performance indicates positive growth, particularly over the 2 to 5-year periods.

How has been the historical performance of Glaxosmi. Pharma?

Glaxosmi. Pharma has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 3,128.12 crore to 3,749.21 crore and profit after tax rising from 445.39 crore to 927.58 crore. The company's operating profit margin improved significantly, reflecting enhanced operational efficiency.

Answer:<BR>The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Glaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably from 26.29 in March 2019 to 54.75 in March 2025. On the balance sheet, total assets grew from 3,025.05 crore in March 2020 to 3,967.20 crore in March 2025, while total liabilities increased from 3,025.05 crore to 3,967.20 crore during the same period. The cash flow from operating activities improved significantly, reaching 1,289 crore in March 2025 compared to 490 crore in March 2020, indicating enhanced operational efficiency and cash generation capabilities.

Is Glaxosmi. Pharma technically bullish or bearish?

As of October 30, 2025, Glaxosmi Pharma's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bearish weekly outlook from Dow Theory.

As of 30 October 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly, contributing to the overall bearish sentiment. Although the Dow Theory shows a mildly bearish weekly outlook and a bullish monthly perspective, the prevailing bearish indicators suggest a negative short-term trend for Glaxosmi. Pharma.

Who are the top shareholders of the Glaxosmi. Pharma?

The top shareholders of Glaxosmi. Pharma include Glaxo Group Limited with 35.99%, various promoters, mutual funds holding 5.17%, and 255 foreign institutional investors owning 4.52%. Individual investors account for 10.6% of the shares, indicating a significant concentration of ownership among promoters.

The top shareholders of Glaxosmi. Pharma include the following:<BR><BR>1. **Glaxo Group Limited** - This entity is the largest shareholder, holding 35.99% of the company's shares.<BR>2. **Promoters** - They collectively hold the majority of the shares, although specific percentages beyond Glaxo Group Limited are not detailed.<BR>3. **Mutual Funds** - A total of 36 mutual fund schemes hold 5.17% of the shares.<BR>4. **Foreign Institutional Investors (FIIs)** - 255 FIIs collectively own 4.52% of the company.<BR>5. **SBI Nifty Midcap 150 Index Fund** - This is the highest public shareholder, holding 1.27%.<BR>6. **Individual Investors** - They account for 10.6% of the shareholding.<BR><BR>This distribution highlights a significant concentration of ownership among the promoters, particularly Glaxo Group Limited.

Is Glaxosmi. Pharma overvalued or undervalued?

As of November 16, 2023, Glaxosmi. Pharma is considered very expensive and overvalued with a PE ratio of 62.68, significantly higher than its peers, despite a strong ROE of 47.36% and a year-to-date return of 53.11%.

As of 16 November 2023, Glaxosmi. Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 62.68, an EV to EBITDA ratio of 47.07, and a Price to Book Value of 29.69, all of which are substantially higher than industry norms.<BR><BR>In comparison to its peers, Glaxosmi. Pharma's PE ratio is notably higher than Sun Pharma's 35.25 and Cipla's 22.99, which are categorized as expensive and attractive, respectively. Additionally, the company's ROE stands at a remarkable 47.36%, yet this is overshadowed by its very high valuation metrics. Despite outperforming the Sensex with a year-to-date return of 53.11% compared to the Sensex's 5.63%, the elevated valuation ratios suggest that the stock may not be a prudent investment at this time.

When is the next results date for Glaxosmi. Pharma?

No Upcoming Board Meetings

What is the bonus history of the Glaxosmi. Pharma?

Glaxosmithkline Pharmaceuticals Ltd issued a 1:1 bonus share on September 11, 2018, with a record date of September 13, 2018, meaning shareholders received one additional share for each share held.

Glaxosmi. Pharma, officially known as Glaxosmithkline Pharmaceuticals Ltd, has a notable bonus history. The most recent bonus issue was a 1:1 bonus, which was announced with an ex-date of September 11, 2018. The record date for this bonus was September 13, 2018. This means that shareholders received one additional share for every share they held as of the record date. If you have any more questions about the company or its financials, feel free to ask!